Navigation Links
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
Date:6/30/2008

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for SGX393. This compound is an internally developed, selective, orally-bioavailable small molecule for the treatment of relapsed and refractory chronic myelogenous leukemia (CML).

The standard of care for CML is Gleevec(R). Although Gleevec is a highly effective front-line therapy for CML, there are patients who relapse while on Gleevec or who are intolerant to the therapy. In the majority of cases, relapses have been linked to the emergence of a number of drug-resistant mutant forms of the tyrosine kinase BCR-ABL. The single mutant that has been the most challenging to inhibit is the T315I mutant. Neither Gleevec nor the two more recently approved CML treatments, Sprycel(R) and Tasigna(R), inhibit the T315I mutant. SGX393 inhibits both wild-type BCR-ABL and many drug resistant mutant forms of BCR-ABL, including the T315I mutation.

"Filing of this IND submission represents another testament to our internal capabilities. We continue to focus on moving our discovery and development programs forward," said Mike Grey, CEO of SGX Pharmaceuticals.

About SGX393

SGX393 was discovered by SGX utilizing FAST(TM), its fragment based approach to drug discovery. SGX393 initially fell within the purview of the Company's collaboration with the Novartis Institute for Biomedical Research (Novartis). SGX obtained the right to further develop and commercialize SGX393 following an amendment to its agreement with Novartis that was signed in September 2007, and it is subject to a reacquisition right of Novartis which may be exercis
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIA Pharmaceuticals Set to Join Russell Microcap Index
2. Wyeth Pharmaceuticals Announces Organizational Change
3. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
6. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
7. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
8. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
9. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Madison, Wis. - Stratatech Corp. has received ... Institute on Aging , a division of the National ... gene therapy products for the use in the treatment of ... stasis and pressure ulcers. , ,It is estimated that in ...
... Brookfield, Wis.-based Fiserv, Inc. and CUNA ... delivery and presentation of CUNA Mutual's payment ... with the technology solutions offered by Fiserv ... CUNA Mutual's payment protection products, which include credit life, ...
... Wis. -- We take it for granted the lights ... and ice storms can temporarily bring down power lines and ... of us believe affordable power will always be there - ... ,If only it was as easy as flipping a switch. ...
Cached Biology Technology:Keeping Wisconsin supplied with energy won't get any easier 2Keeping Wisconsin supplied with energy won't get any easier 3
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
(Date:4/17/2014)... White House honored Clemson professor Rajendra Singh Thursday ... to promote and expand solar deployment in the ... D. Houser Banks Professor of Electrical and Computer ... Nanoelectronics, is considered a local hero leading the ... economic opportunity in solar power and driving policy ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... orchids are found in habitats where light may be ... surprising that many achlorophyllous (lacking chlorophyll), as well as ... supply them with carbohydrates in order to grow. However, ... and range in their photosynthetic capabilities. For those ...
... 07/07/11, Clearwater Beach, FL. Research to be presented ... Study of Ingestive Behavior (SSIB), the foremost society for research ... ghrelin, a naturally occurring gut hormone, increases our willingness to ... for non-food items. Have you ever wondered about why ...
... developing limbs and digits were present in primitive fish ... to land, researchers have discovered. Genetic switches control ... particular switch taken from fish DNA is placed into ... developing limb region of embryos, University of Chicago researchers ...
Cached Biology News:Orchids and fungi: An unexpected case of symbiosis 2Orchids and fungi: An unexpected case of symbiosis 3Orchids and fungi: An unexpected case of symbiosis 4Genetic switch for limbs and digits found in ancient fish 2Genetic switch for limbs and digits found in ancient fish 3
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Biology Products: